Oncological Outcomes After Hippocampus-Sparing Whole-Brain Radiotherapy in Cancer Patients With Newly Diagnosed Brain Oligometastases: A Single-Arm Prospective Observational Cohort Study in Taiwan

Shinn-Yn Lin1,2†, Din-Li Tsan1†, Chi-Cheng Chuang3,4†, Chi-Cheng Yang5, Ping-Ching Pai1,2, Chih-Liang Wang4,6, Yi-Ming Wu4,7, Cheng-Chi Lee3,4†, Chia-Hsin Lin1,8, Kuo-Chen Wei3,4 and Wen-Chi Chou4,9*

1 Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, 2 Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan, 3 Department of Neurosurgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, 4 College of Medicine, Chang Gung University, Taoyuan, Taiwan, 5 Department of Psychology, National Chengchi University, Taipei, Taiwan, 6 Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 7 Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, 8 School of Medicine, National Yang-Ming University, Taipei, Taiwan, 9 Department of Hematology-Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan

Background: Promisingly, the technique of hippocampus sparing during WBRT (HS-WBRT) might preserve NCFs. In this research, we examined oncological outcomes, with emphasis on neurologic/non-neurologic causes of death, CNS progression, and leptomeningeal disease (LMD) recurrence in cancer patients who underwent HS-WBRT.

Methods: One hundred and fourteen cancer patients with newly diagnosed brain oligometastases underwent HS-WBRT were consecutively enrolled. The cumulative incidence of cancer-specific deaths (neurologic or non-neurologic), LMD recurrence, and the composite endpoint of CNS progression (CNS-CE) as the first event were computed with a competing-risks approach to characterize the oncological outcomes after HS-WBRT.

Results: Patients with intact brain metastases had a significantly increased likelihood of dying from non-neurologic causes of death associated with early manifestation of progressive systemic disease (hazard ratio for non-neurologic death, 1.78; 95% CI, 1.08–2.95; p = 0.025; competing-risks Fine–Gray regression), which reciprocally rendered them unlikely to encounter LMD recurrence or any pattern of CNS progression (HR for CNS-CE as the first event, 0.13; 95% CI, 0.02–0.97; p = 0.047; competing-risks Fine–Gray regression). By contrast, patients with resection cavities post-
cranial death (neurologic/non-neurologic) (11, 12). Herein, this
competing risks of death or a mutually exclusive cancer-speci
irradiation, were explored thoroughly taking into account the
various neuro-oncological outcomes, including the cumulative
Moreover, isodose distribution speci
intracranial and extracranial therapies (9, 10). Additionally,
oncologists in prioritizing and escalating the intensity of
patients receiving cranial irradiation for treating primary brain
negatively correlated with neuropsychological performance in
neurogenesis is strongly associated with cognitive dysfunction (5).
WBRT) for managing brain oligometastases has preserved
sparing of the centrally located hippocampus while delivering
WBRT without special requirements for conformal radiotherapy
in real-world practice.
The hippocampus plays a vital role in maintaining memory
functions (3). Brain irradiation, particularly WBRT, is detrimental
to hippocampal neurogenesis (4), and impaired stem-cell
neurogenesis is strongly associated with cognitive dysfunction (5).
Moreover, isodose distribution specific to the hippocampus is
negatively correlated with neuropsychological performance in
patients receiving cranial irradiation for treating primary brain
tumors (6). Therefore, hippocampus sparing during WBRT (HS-
WBRT) for managing brain oligometastases has preserved
neurocognitive functions (NCFs) (7). Besides, the use of volumetric
modulated arc therapy or helical tomotherapy provides conformal
sparring of the centrally located hippocampus while delivering
uniform dose to the remaining brain parenchyma (8).
To better characterize survival outcomes in cancer patients
with oligometastatic brain disease after receiving HS-WBRT,
clarifying the cancer-specific causes of death and attributing
them to neurologic or non-neurologic cause will assist neuro-
oncologists in prioritizing and escalating the intensity of intracranial and extracranial therapies (9, 10). Additionally,
various neuro-oncological outcomes, including the cumulative incidence of leptomeningeal disease (LMD) after brain
irradiation, were explored thoroughly taking into account the
competing risks of death or a mutually exclusive cancer-specific
cause of death (neurologic/non-neurologic) (11, 12). Herein, this
long-term follow-up report aims mostly to explore the
meaningful influences of patient-, disease-, and treatment-
related variables on the risk of neurologic death, or non-
neurologic death, and oncological outcomes with particular emphasis on CNS progression.

INTRODUCTION

Approximately 20%–40% of patients with brain cancer have
brain metastasis (BM), resulting in poor prognosis (1). Owing to
advances in diagnosis and treatment, many patients with BM, a
common adult intracranial neoplasm, are surviving longer.
Traditionally, whole-brain radiation therapy (WBRT), with or
without surgical resection, might be the treatment of choice for managing BMs.

According to the latest treatment guidelines of the National
Comprehensive Cancer Network (2), surgical resection improves
oncological outcomes in cancer patients with newly diagnosed
BMs. Alternatively, stereotactic radiotherapy (SRS) can be used
in patients with oligometastatic brain disease and surgery-related
morbidity. Most patients with multiple and disseminated BM
lesions can be effectively managed initially with conventional
WBRT without special requirements for conformal radiotherapy
in real-world practice.
The hippocampus plays a vital role in maintaining memory
functions (3). Brain irradiation, particularly WBRT, is detrimental
to hippocampal neurogenesis (4), and impaired stem-cell
neurogenesis is strongly associated with cognitive dysfunction (5).
Moreover, isodose distribution specific to the hippocampus is
negatively correlated with neuropsychological performance in
patients receiving cranial irradiation for treating primary brain
tumors (6). Therefore, hippocampus sparing during WBRT (HS-
WBRT) for managing brain oligometastases has preserved
neurocognitive functions (NCFs) (7). Besides, the use of volumetric
modulated arc therapy or helical tomotherapy provides conformal
sparring of the centrally located hippocampus while delivering
uniform dose to the remaining brain parenchyma (8).
To better characterize survival outcomes in cancer patients
with oligometastatic brain disease after receiving HS-WBRT,
clarifying the cancer-specific causes of death and attributing
them to neurologic or non-neurologic cause will assist neuro-
oncologists in prioritizing and escalating the intensity of intracranial and extracranial therapies (9, 10). Additionally,
various neuro-oncological outcomes, including the cumulative incidence of leptomeningeal disease (LMD) after brain
irradiation, were explored thoroughly taking into account the
competing risks of death or a mutually exclusive cancer-specific
cause of death (neurologic/non-neurologic) (11, 12). Herein, this
long-term follow-up report aims mostly to explore the
meaningful influences of patient-, disease-, and treatment-
related variables on the risk of neurologic death, or non-
neurologic death, and oncological outcomes with particular emphasis on CNS progression.

METHODS

Patient Selection

In this prospective study, 114 brain irradiation-naive cancer patients
were consecutively enrolled between March 2013 and December
2020. The study protocol was approved by the Institutional Review
Board at our institute (IRB 101-4151B and 103-1090C), and all
participants provided written informed consent. The recruited
patients were adult cancer patients with radiotherapy-naive brain
oligometastases and a fair/good performance status. All recruited
patients had a limited BM disease burden, termed oligometastatic
brain disease, as previously described by us (8).

Pretreatment Evaluations and
Clinical Follow-Up

To ensure no detectable BM within a 5-mm margin around
either hippocampus, all participants received gadolinium-
enhanced MRI within 1 month before undergoing HS-WBRT,
regardless of whether they had received preceding neurosurgical
resection. Furthermore, all enrolled participants underwent
baseline neurocognitive assessment within 2 weeks before the
start of HS-WBRT.

After the standardized course of HS-WBRT, adhering to our
study protocol (8), was administered, brain MRI examination
was carried out at 4 and 12 months after HS-WBRT. All
recruited patients were regularly followed up and surveyed for
detecting the occurrence of CNS progression/failure suspected
radiographically and clinically throughout the study period.
Three patterns of CNS progression/failure were classified:
intracranial local failure (LF), distant brain parenchymal failure
(DBF), and development of LMD. All the enrolled patients were
followed up until death or June 1, 2021.

Statistical Considerations and Analyses

Various oncological outcomes in addition to overall survival
(OS) were evaluated, with special emphasis on the cumulative
incidence of several neuro-oncological endpoints, including neurologic/non-neurologic death (9, 10), LMD recurrence, and CNS progression as the first event (13). The events in relation to CNS progression were measured as a composite endpoint (CNS-CE), comprising three patterns of CNS progression: local recurrence, distant brain recurrence, and LMD. These three patterns of CNS progression/failure can manifest individually, synchronously, or metachronously. CNS progression is defined as radiographic/clinical evidence of progressively enlarging brain metastatic lesion(s) or any clinical situation suggesting the occurrence of LMD.

With death as a competing risk, the cumulative incidence probability of CNS progression as the first event (13) was computed with a competing-risks approach (12), with statistical values adjusted for the competing risks of death or pre-existing non-CNS progression. The effects of multiple covariates and potentially meaningful confounding factors were investigated with the Fine–Gray proportional hazards model (12). The Statistical Package for Social Sciences, version 20.0 (SPSS, Chicago, IL, USA) was used for statistical analyses.

RESULTS

Patient Characteristics

A total of 114 patients were analyzed in this prospective study, with a median follow-up of 19.6 months (range, 0.43–95.0) for all consecutively recruited patients and 36.2 months (range, 10.5–95.0) for the surviving patients. These 114 patients were further categorized into two clinical subcohorts depending on whether upfront craniotomy plus tumor resection was performed, with surgical cavities post-craniotomy (n = 85) and without (n = 29).

The demographics and clinical characteristics of all 114 patients are listed in Table 1. As shown in Table 1, 54 males (47.4%) and 60 females (52.6%) were enrolled, with a median age of 57.3 years at registration. Most participants (81.6%) had a fair/satisfactory performance status (ECOG performance status 0–1). Fewer patients had a favorable performance status (KPS 90 or better) in the subcohort undergoing recent craniotomy plus tumor removal. The majority of the participants had primary lung cancer (predominantly lung adenocarcinoma) or breast cancer as their primary malignancy; 22 patients (19.3%) have miscellaneous malignancies as their primary cancer. A higher percentage of solitary BM was present in the subcohort undergoing upfront craniotomy plus tumor resection.

OS and CNS Progression After HS-WBRT

There were eighty-eight deaths (77.2%) at the end of the study. Among the deceased patients, 85 patients (74.6%) died of cancer-related causes of death, and 31 (27.2%) died of neurologic causes directly resulting from their BM per se. However, 66 (57.9%) cancer-specific deaths were attributed to non-neurologic causes associated with systemic (extracranial) progression.

Regarding Kaplan–Meier, estimates of OS are portrayed in Figure 1A. There was no significant difference in OS between two subcohorts with oligometastatic brain disease (patients with resection cavities post-craniotomy versus those with intact BMs). Additionally, Table 2 reveals that several characteristics that may pose increased hazards to OS in patients undergoing HS-WBRT included suboptimal performance status (KPS < 90 or ECOG worse than 1) before receiving HS-WBRT, diminished activities of daily living (indicated by Barthel index or FIM scale), histological subtype of the primary cancer (Figure 1B), and the status of extracranial involvement at recruitment (Figure 1C). Similarly, it appears that the prognostic classification grouping according to RTOG Recursive Partitioning Analysis also conveys survival impact (Figure 1D). After controlling for these clinically significant characteristics, the impact of craniotomy plus tumor resection (versus intact BMs) on OS still failed to be statistically significant (adjusted HR, 1.257; 95% CI, 0.725–2.182; \( p = 0.045 \)) (Table 2).

Oncological Outcomes and Competing-Risks Analyses

Figure 2A illustrates the overall cumulative incidence curves of neurologic death and non-neurologic death, respectively. The median time to neurologic death was 19.8 months (95% CI, 15.8 to 23.8), whereas the median time to non-neurologic death was 15.6 months (95% CI, 19.2 to 35.1). At 12 months, the cumulative incidence rates of the two principal causes of death (which were not always mutually exclusive) were 8.77% for neurologic death and 24.6% for non-neurologic death, respectively.

As displayed in Table 2, competing-risks analyses disclosed that despite not always reaching statistical significance, the following clinical factors tended to be associated with increased or decreased likelihoods of neurologic death: breast cancer or miscellaneous malignancies apart from primary lung cancers (Figures 2B, C), an uncontrolled/untreated extracranial status (Figure 2D), and belonging to the subcohort with intact BMs (versus that with resection cavities post-craniotomy) at study enrollment (Figure 2E).

For HS-WBRT-treated patients, the clinical characteristics predisposing our patients who received HS-WBRT to an increased risk of dying from progressive systemic disease (non-neurologic death) include suboptimal activities of daily living, an uncontrolled/untreated status of extracranial involvement (Figure 2D), and being in the subgroup of intact BMs (Figure 2E) because no craniotomy was recommended or attempted. The competing-risks models are exhibited in Tables 2 and 3.

Figures 2E, F show the differences between the two distinct scenarios (intact BMs versus cavities post-craniotomy in probabilities of neurologic/non-neurologic deaths). Owing to the mutually exclusive nature of competing-risks effects exerted by either neurologic or non-neurologic death, the predominantly high incidence of non-neurologic death, which usually occurred earlier in the subcohort with intact BMs, apparently rendered those with intact BMs relatively unlikely to die of neurologic death. Specifically, the patients with intact BMs were significantly more likely to die from progressive extracranial disease (HR, 1.78; 95% CI, 1.08–2.95; \( p = 0.025 \)) compared with those with resection cavities post-craniotomy. Consequently, patients with intact BMs were unlikely to survive long enough to encounter the threats of
neurologic death (HR, 0.08, 95% CI, 0.01–0.60; p = 0.013, Figure 2E) than those with surgical cavities post-craniotomy. After being adjusted to control for other clinically relevant characteristics, the adjusted HR for non-neurologic death in the subcohort of intact BMs was 1.88 times higher than in the subcohort with resection cavities post-craniotomy (adjusted HR, 1.88; p = 0.026; Figure 2F). In addition, adjusted HRs of clinical characteristics predicting neurologic/non-neurologic death were computed iteratively after controlling for other available covariates (Table 2).

LMD recurrence after HS-WBRT was observed clinically and radiographically in all of the 114 patients. Figure 3A illustrates that the cumulative incidence of CNS progression manifesting as LMD recurrence after HS-WBRT was 5.26% at 12 months, 7.98% TABLE 1 | Patient demographics, tumor, disease, and treatment-related characteristics in the 114 patients with newly diagnosed brain oligometastases.

| Characteristics                              | Entire cohort of brain oligometastases (n = 114) | Surgical cavities (n = 85) | Intact metastases (n = 29) | p-value |
|----------------------------------------------|-------------------------------------------------|---------------------------|---------------------------|---------|
| Age at registration                          |                                                 |                           |                           | 0.32    |
| Mean (SD)                                    | 57.4 (9.7)                                      | 56.5 (8.9)                | 60.0 (11.3)               |         |
| Median (IQR)                                 | 57.3 (12.9)                                     | 56.6 (14.0)               | 59.7 (9.9)                |         |
| Range                                        | 26.7–83                                        | 28.30–77.20               | 26.70–83.00               |         |
| <65                                          | 90 (78.96%)                                     | 69 (81.18%)               | 21 (72.41%)               |         |
| ≥65                                          | 24 (21.05%)                                     | 16 (19.82%)               | 8 (27.59%)                |         |
| Gender                                       |                                                 |                           |                           | 0.59    |
| Female                                       | 60 (52.6%)                                      | 46 (54.1%)                | 14 (48.3%)                |         |
| Male                                         | 54 (47.4%)                                      | 39 (45.9%)                | 15 (51.7%)                |         |
| KPS performance status                       |                                                 |                           |                           | 0.022*  |
| KPS ≥ 90                                     | 50 (43.9%)                                      | 32 (37.65%)               | 18 (62.1%)                |         |
| 70 ≤ KPS < 90                                | 64 (56.1%)                                      | 53 (62.35%)               | 11 (37.9%)                |         |
| ECOG performance status                      |                                                 |                           |                           | 0.016*  |
| 0–1                                          | 93 (81.6%)                                      | 65 (78.5%)                | 28 (96.55%)               |         |
| 2                                            | 21 (18.4%)                                      | 20 (23.5%)                | 1 (3.45%)                 |         |
| Baseline Barthel index                        |                                                 |                           |                           | 0.37    |
| Mean (SD)                                    | 92.59 (15.83)                                   | 91.24 (17.52)             | 96.55 (8.25)              |         |
| Median (IQR)                                 | 100 (5)                                        | 100 (10.0)                | 100 (2.5)                 |         |
| Full, 100                                    | 79 (69.3%)                                      | 57 (67.1%)                | 22 (75.9%)                |         |
| <100                                         | 35 (30.7%)                                      | 28 (32.9%)                | 7 (24.1%)                 |         |
| Baseline FIM scale                           |                                                 |                           |                           | 0.45    |
| Mean (SD)                                    | 117.74 (16.00)                                  | 116.28 (17.54)            | 122.00 (9.25)             |         |
| Median (IQR)                                 | 125 (10)                                       | 125 (12)                   | 126 (2)                   |         |
| Full, 126                                    | 58 (49.1%)                                      | 40 (47.1%)                | 16 (55.2%)                |         |
| <126                                         | 58 (50.9%)                                      | 45 (52.9%)                | 13 (44.8%)                |         |
| Histological subtype of primary cancer       |                                                 |                           |                           | 0.004*  |
| Lung, adenocarcinoma                         | 64 (56.1%)                                      | 41 (48.2%)                | 23 (79.3%)                |         |
| EGFR mutant                                  | 36 (31.6%)                                      | 23 (27.1%)                | 13 (44.8%)                |         |
| EGFR wild type                               | 26 (22.8%)                                      | 16 (18.8%)                | 10 (34.5%)                |         |
| ALK mutation                                 | 2 (1.8%)                                        | 2 (2.4%)                  | 0 (0.0%)                  |         |
| Lung, non-adenocarcinoma                     | 11 (9.7%)                                       | 7 (8.2%)                  | 4 (13.8%)                 |         |
| Breast                                       | 17 (14.9%)                                      | 17 (20.0%)                | 0 (0.0%)                  |         |
| Her-2 overexpression                         | 6 (5.3%)                                        | 6 (7.1%)                  | 0 (0.0%)                  |         |
| Triple negative                              | 8 (7.0%)                                        | 9 (9.4%)                  | 0 (0.0%)                  |         |
| ER or PR positive                            | 3 (2.6%)                                        | 3 (3.6%)                  | 0 (0.0%)                  |         |
| Others*                                      | 22 (19.3%)                                      | 20 (23.5%)                | 2 (6.9%)                  |         |
| Number of brain metastatic lesions           |                                                 |                           |                           | 0.07    |
| Solitary                                     | 71 (62.3%)                                      | 57 (67.1%)                | 14 (48.3%)                |         |
| 2–3                                          | 43 (37.7%)                                      | 28 (32.9%)                | 15 (51.7%)                |         |
| The technique of SIB                        |                                                 |                           |                           | 0.022*  |
| Not applied                                  | 64 (56.1%)                                      | 53 (62.36%)               | 11 (37.9%)                |         |
| Attempted                                    | 50 (43.9%)                                      | 32 (37.65%)               | 18 (62.1%)                |         |
| Status/control of extracranial disease       |                                                 |                           |                           | 0.016*  |
| Stable or controlled                         | 26 (22.8%)                                      | 24 (28.2%)                | 2 (6.9%)                  |         |
| Uncontrolled yet                             | 88 (77.2%)                                      | 61 (71.8%)                | 27 (93.1%)                |         |
| RTOG RPA class                               |                                                 |                           |                           | 0.012*  |
| Class I                                      | 22 (19.3%)                                      | 21 (24.7%)                | 1 (3.45%)                 |         |
| Class II                                     | 92 (80.7%)                                      | 64 (75.3%)                | 28 (96.55%)               |         |

HS-WBRT, hippocampus-sparing whole-brain radiotherapy; KPS, Karnofsky performance status; ECOG, Eastern Cooperative Oncology Group; FIM, functional independence measure; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; Her-2, human epidermal growth factor receptor; ER, estrogen receptor; PR, progesterone receptor; SIB, simultaneous integrated boost; RTOG RPA class, Radiation Therapy Oncology Group recursive partitioning analysis.

*The 22 patients with other histology type including hepatocellular carcinoma (4), colorectal cancer (3), esophageal cancer (2), unknown primary cancer (2), sarcoma (2), neuroendocrine carcinoma of uterine cervix (1), embryonal carcinoma (1), malignant melanoma (1), endometrial adenocarcinoma (1), urinary bladder cancer (1), renal cell carcinoma (3), and gastric cancer (1).

*Asterisk symbols indicate statistically significant values (p < 0.05).
at 18 months, and 7.98% at 24 months. The median time to develop LMD occurrence in the 10 patients was only 9.77 months from the date of being enrolled. Likewise, the cumulative incidence of the composite endpoint of CNS progression (CNS-CE) as the first event is also illustrated in the same plot (Figure 3A).

As mentioned above, dying from cancer-specific causes of death, which was assumed non-neurologic, would usually manifest considerably earlier than would any event resulting from CNS progression. Therefore, the CNS-CE as the first event was computed, accounting for the competing risks of either non-CNS progression or death, whichever happened first. Overall, the median time to such event was only 10.6 months from the date of being enrolled. The cumulative incidence rate of CNS-CE as the first event in the entire cohort of 114 patients was 10.5% at 12 months, 14.9% at 24 months, 17.7% at 3 years, and 18.7% at 4 years (Figure 3A).

Figure 3B and Supplementary Figure 1 illustrate the remarkable differences in either CNS-CE as the first event or LMD recurrence after undergoing HS-WBRT. CNS-CE as the first event was 23.8% in the subcohort with surgical cavities and only 3.49% in the subcohort with intact BMs (hazard ratio, 0.13; \( p = 0.047 \); Figure 3B), and no LMD recurrence was found in patients with intact BMs (Table 3). Moreover, as illustrated in Figure 3C, under the substantial impacts exerted by non-neurologic death, which usually manifests early and fatally, the associations between the initial status of extracranial involvement and neuro-oncological outcomes (either LMD recurrence or CNS-CE as the first event) were similar. Lastly, as for the association between histopathology of primary malignancy and the oncological outcomes of concern, it seemed that there was a tendency toward increased likelihoods of developing CNS progression if the primary malignancy was not of lung adenocarcinoma origin (HR for CNS-CE as first event, 2.28; 95% CI, 0.95–5.45; \( p = 0.065 \); Figure 3D). Although not statistically significant, some clinical characteristics appeared to be associated with the occurrence of CNS-CE without pre-existing non-CNS progression or death (Table 3, Supplementary Figures 1, 2, and Figure 3).

**DISCUSSION**

In this prospective neurocognitive study, satisfactory oncological outcomes were observed through hippocampus sparing during the WBRT in the treatment of cancer patients who had brain oligometastases and a fair to good performance status. The important oncological outcomes, such as cumulative incidence of LMD recurrence and neurologic (or non-neurologic) cancer-specific death while treated with HS-WBRT, can greatly help neuro-oncologists in managing patients with oligometastatic brain disease.

The fundamental issue underlying cancer-related death is predicting which patients who have undergone HS-WBRT die from their brain oligometastases. Focusing on oncological outcomes-directed analyses would assist us in clarifying whether some certain cancer patients with brain oligometastases have an overwhelmingly increased risk of non-neurologic death despite the
### TABLE 2 | Two patterns of cancer-specific deaths based on competing-risks analyses.

| Covariate/parameter | OS | Neurologic death | Non-neurologic death |
|---------------------|----|-----------------|----------------------|
|                     | Crude HR (95% CI) | Adjusted HR (95% CI) | Crude HR (95% CI) | aHR (95% CI) | Crude HR (95% CI) | aHR (95% CI) |
|                     | p-value | p-value | p-value | p-value | p-value | p-value |
| **Subcohort**       |        |        |        |        |        |        |
| Surgical cavities   | 1.117 (0.688–1.812) | 1.257 (0.725–2.182) | 0.082 (0.011–0.595) | 0.013 | 1.778 (1.076–2.940) | 0.039 |
|                     | 0.065 | 0.42 | 0.019 | 0.009 | 0.025 | 0.026 |
| Age at enrollment   |        |        |        |        |        |        |
|                     | 0.984 (0.963–1.006) | 0.981 (0.943–1.021) | 0.990 (0.967–1.014) | 0.35 | 0.40 |
| Gender              |        |        |        |        |        |        |
| Female              | 1 | 1 | 1 | 1 | 1 |
| Male                | 0.816 (0.536–1.243) | 1.601 (0.780–3.737) | 0.790 (0.491–1.272) | 0.34 |
| **KPS just before the HS-WBRT course** |        |        |        |        |        |        |
| KPS ≥ 90            | 1 | 1 | 1 | 1 | 1 |
| 70 ≤ KPS < 90       | 1.470 (0.956–2.260) | 1.563 (0.943–2.260) | 1.601 (0.760–3.737) | 0.22 | 1.163 (1.030–2.601) | 0.56 |
| 50 ≤ KPS < 70       | 1.556 (1.065–2.273) | 1.278 (0.674–2.273) | 1.756 (0.877–3.516) | 0.11 | 1.636 (1.032–2.601) | 0.56 |
| Baseline ECOG performance status |        |        |        |        |        |        |
| 0–1                 | 1 | 1 | 1 | 1 | 1 |
| 2                   | 1.556 (1.065–2.273) | 1.278 (0.674–2.273) | 1.756 (0.877–3.516) | 0.11 | 1.636 (1.030–2.601) | 0.56 |
| 3                   | 1 | 1 | 1 | 1 | 1 |
| 4                   | 1.662 (1.071–2.580) | 1.765 (1.121–2.580) | 0.723 (0.323–1.618) | 0.43 | 2.147 (1.302–3.542) | 0.03 |
| 5                   | 1 | 1 | 1 | 1 | 1 |
| 6                   | 1.662 (1.071–2.580) | 1.765 (1.121–2.580) | 0.723 (0.323–1.618) | 0.43 | 2.147 (1.302–3.542) | 0.03 |
| Barthe index        |        |        |        |        |        |        |
| A continuous variable | 0.983 (0.970–0.995) | 1.002 (0.974–1.031) | 0.978 (0.964–0.993) | 0.90 | 0.004 |
| Full, 100           | 1 | 1 | 1 | 1 | 1 |
| <100                | 1.662 (1.071–2.580) | 1.765 (1.121–2.580) | 0.723 (0.323–1.618) | 0.43 | 2.147 (1.302–3.542) | 0.03 |
| FIM scale           |        |        |        |        |        |        |
| A continuous variable | 0.983 (0.971–0.996) | 0.999 (0.974–1.025) | 0.978 (0.983–0.994) | 0.96 | 0.007 |
| Full, 126           | 1 | 1 | 1 | 1 | 1 |
| <126                | 1.204 (0.790–1.838) | 1.324 (0.859–1.838) | 0.651 (0.323–1.312) | 0.23 | 1.720 (1.062–2.785) | 0.027 |
| Histological subtype of primary cancer |        |        |        |        |        |        |
| Lung, adenocarcinoma | 1 | 1 | 1 | 1 | 1 |
| Lung, non-adenocarcinoma | 0.905 (0.443–1.848) | 1.054 (0.507–1.848) | 1.755 (0.483–6.374) | 0.39 | 1.086 (0.517–2.280) | 0.039 |
| Breast              | 0.677 (0.363–1.262) | 0.986 (0.462–1.262) | 4.445 (1.964–10.062) | 0.001 | 0.566 (0.286–1.119) | 0.10 |
| Others or unknown   | 1.659 (0.966–2.850) | 1.947 (1.004–2.850) | 3.653 (1.386–9.640) | 0.09 | 0.920 (0.443–1.913) | 0.50 |
| (Continued)          |        |        |        |        |        |        |
| Covariate/parameter | OS | Neurologic death | Non-neurologic death |
|---------------------|-----------------|-----------------|---------------------|
|                     | Crude HR (95% CI) | Adjusted HR (95% CI) | Crude HR (95% CI) aHR (95% CI) | Crude HR (95% CI) aHR (95% CI) |
|                     | p-value | p-value | p-value | p-value |

**Whether the primary cancer was lung adenocarcinoma or not**

|                | Reference | Reference | Reference | Reference |
|----------------|-----------|-----------|-----------|-----------|
| Lung adenocarcinoma | 1.018 (0.663–1.562) | 1.276 (0.761–2.140) | 3.432 (1.597–7.375) | 2.647 (1.209–5.796) |
| All others       | 1         | Reference | 1         | Reference |
| p = 0.94        | p = 0.36  | p = 0.002 | p = 0.015 | p = 0.4 |

**Number of brain metastatic lesions**

|                | Reference | Reference | Reference | Reference |
|----------------|-----------|-----------|-----------|-----------|
| Solitary       | 1.165 (0.754–1.801) | 1.246 (0.782–1.801) | 0.816 (0.388–1.717) | 1.084 (0.513–1.717) |
| 2–3 metastatic foci | 1       | Reference | 1         | Reference |
| p = 0.49       | p = 0.36  | p = 0.59  | p = 0.83  | p = 0.5 |

**Extent of resection**

|                | Reference | Reference | Reference | Reference |
|----------------|-----------|-----------|-----------|-----------|
| En-bloc gross total | 1.221 (0.555–2.687) | 1.506 (0.553–4.102) | 1.352 (0.496–3.686) | 1         |
| Less than gross total | 1         | Reference | 1         | Reference |
| p = 0.62       | p = 0.42  | p = 0.56  | p = 0.96  | p = 0.96  |

**The technique of SIB**

|                | Reference | Reference | Reference | Reference |
|----------------|-----------|-----------|-----------|-----------|
| Not applied     | 1.154 (0.743–1.793) | 0.491 (0.219–1.098) | 1.256 (0.770–2.049) | 1         |
| Attempted      | 1         | Reference | 1         | Reference |
| p = 0.52       | p = 0.08  | p = 0.36  | p = 0.36  | p = 0.36  |

**Status and control of extracranial disease**

|                | Reference | Reference | Reference | Reference |
|----------------|-----------|-----------|-----------|-----------|
| Stable or controlled | 2.005 (1.180–3.406) | 2.111 (1.128–3.406) | 0.340 (0.174–0.663) | 1.084 (0.513–1.717) |
| Untreated yet or uncontrolled | 1         | Reference | 1         | Reference |
| p = 0.010       | p = 0.019 | p = 0.002 | p = 0.21  | p = 0.0001 |

**RTOG RPA class**

|                | Reference | Reference | Reference | Reference |
|----------------|-----------|-----------|-----------|-----------|
| Class I        | 1.734 (0.992–3.031) | 0.344 (0.175–0.675) | 4.677 (1.942–11.262) | 1         |
| Class II       | 1         | Reference | 1         | Reference |
| p = 0.053      | p = 0.002 | p = 0.001 | p = 0.001 | p = 0.001 |

OS, overall survival; PCI, primary cranial irradiation; aHR, adjusted hazard ratio; KPS, Karnofsky performance status; HS-WBRT, hippocampus-sparing whole-brain radiotherapy; ECOG, Eastern Cooperative Oncology Group; FIM, functional independence measure; SIB, simultaneous integrated boost; RTOG RPA, Radiation Therapy Oncology Group recursive partitioning analysis.

*aAdjusted to control for the other five covariates which are also clinically significant or relevant: 1) age at enrollment, 2) baseline ECOG performance status just before the HS-WBRT course, 3) histological subtype, 4) number of brain metastatic lesions, and 5) status of extracranial disease.

*bAdjusted by the other four covariates which are considered clinically relevant or significant: 1) age at enrollment, 2) histological subtype, 3) ECOG performance status, and 4) status of extracranial disease.

*cAdjusted to control for the other three clinically important characteristics: 1) age at enrollment, 2) baseline ECOG performance status just before the HS-WBRT course, and 3) the two major clinical contexts of arranging the course of HS-WBRT (intact BMs versus resection cavities post-craniotomy).

*dAdjusted by the other four covariates which are assumed clinically relevant or significant: 1) age at enrollment, 2) histological subtype, 3) ECOG performance status, and 4) the two major clinical contexts of administering the HS-WBRT course (intact BMs versus resection cavities post-craniotomy).

NA, Not Applicable.

Bold letters indicate statistically significant values (p < 0.05).
benefit in intracranial control achieved through WBRT. Additionally, the impact exerted by neurologic death may be substantially outweighed by death related to the overwhelming competing-risk event of non-neurologic death (9, 10). Non-neurologic death per se is more likely to be a challenging threat associated with progressive systemic disease to neuro-oncologists when treating cancer patients with brain oligometastases.

Consistent with the US large-scale retrospective studies (9, 10), our findings reinforced their reports that lung cancer patients were more likely to die from non-neurologic causes. It was thus concluded that a particularly higher risk of non-neurologic death occurring in patients with lung cancer might reflect the fact that further advance in effective systemic therapies was persistently deserved.

HS-WBRT is a local treatment whose effect is assumed to be local rather than systemic, and its target volume is tailored to the entire intracranial space. An outcome measure like OS may not adequately reflect the treatment effect of HS-WBRT. Therefore, neuro-oncological outcomes involving the concept of CNS progression have been emphasized (14).

Actually the occurrence of leptomeningeal spreading is not common, but CNS progression manifesting as LMD recurrence is usually devastating, leading to neurologic death inevitably (15). Regarding CNS progression manifesting as LMD after adjuvant brain irradiation after craniotomy, there are limited data reported directly on the subgroup receiving post-craniotomy adjuvant WBRT (16). By contrast, concerning LMD recurrence after postoperative SRS irradiating the resection cavity focally, its cumulative incidence is an increasingly recognized issue (17). Surgical resection of BMs per se is a risk factor predisposing cancer patients harboring cavities post-craniotomy to the manifestation of LMD recurrence, compared with those
All oncological outcomes addressed in the current study, including the competing-risks analyses tailored to CNS-CE as the first event and two patterns of cancer-specific death.

| Covariate/parameter | OS | CNS-CE as first event | LMD recurrence | Neurologic death | Non-neurologic death |
|---------------------|----|-----------------------|----------------|------------------|----------------------|
|                     | Crude HR (95% CI) | Crude HR (95% CI) | Crude HR (95% CI) | Crude HR (95% CI) | Crude HR (95% CI) |
|                     | p-value | p-value | p-value | p-value | p-value |
| **Subcohort**       |          |          |          |          |          |
| Surgical cavities   | 1        | 1        | 1        | 1        | 1        |
| Intact metastases   | 1.117 (0.688–1.812) | 0.131 (0.018–0.972) | 0 | 0.082 (0.011–0.595) | 1.778 (1.076–2.940) |
| p = 0.65            |          | p = 0.047 | p < 0.001 | p = 0.013 | p = 0.025 |
| PCI                 | 0.626 (0.271–1.448) | Not analyzed | NA | NA | NA |
| p = 0.27            |          |          |          |          |          |
| **Age at enrollment** |        |          |          |          |          |
| <65                 | 1        | 1        | 1        | 1        | 1        |
| ≥65                 | 0.70 (0.408–1.216) | 0.91 (0.298–2.766) | 0.42 (0.054–3.259) | 0.19 (0.511–2.757) | 0.55 (0.286–1.039) |
| p = 0.21            | p = 0.91 | p = 0.42 | p = 0.19 | p = 0.55 | p = 0.07 |
| **Gender**          |          |          |          |          |          |
| Female              | 1        | 1        | 1        | 1        | 1        |
| Male                | 0.816 (0.536–1.243) | 1.395 (0.572–3.400) | 2.101 (0.541–8.155) | 1.601 (0.760–3.373) | 0.790 (0.491–1.272) |
| p = 0.34            | p = 0.87 | p = 0.28 | p = 0.41 | p = 0.22 | p = 0.33 |
| **KPS performance status just before the HS-WBRT course** | | | | | |
| KPS > 90            | 1        | 1        | 1        | 1        | 1        |
| 70 ≤ KPS < 90       | 1.470 (0.956–2.260) | 2.741 (1.007–7.459) | 1.180 (0.334–4.173) | 1.601 (0.760–3.373) | 1.152 (0.712–1.866) |
| p = 0.08            | p = 0.048 | p = 0.80 | p = 0.22 | p = 0.56 |          |
| **ECOG performance status** | | | | | |
| 0–1                 | 1        | 1        | 1        | 1        | 1        |
| 2                   | 1.556 (1.065–2.273) | 1.896 (0.734–4.897) | 3.013 (0.860–10.563) | 1.756 (0.877–3.516) | 1.636 (1.030–2.601) |
| p = 0.022           | p = 0.19 | p = 0.09 | p = 0.11 | p = 0.037 |          |
| **Barthel index**   |          |          |          |          |          |
| A continuous variable | 0.983 (0.970–0.995) | 0.980 (0.959–1.001) | 0.966 (0.942–1.053) | 1.002 (0.974–1.031) | 0.978 (0.964–0.993) |
| p = 0.006           | p = 0.07 | p = 0.90 | p = 0.90 | p = 0.004 |          |
| Full, 100           | 1        | 1        | 1        | 1        | 1        |
| <100                | 1.682 (1.071–2.580) | 1.175 (0.472–2.921) | 0.549 (0.116–2.601) | 0.723 (0.323–1.618) | 2.147 (1.302–3.542) |
| p = 0.023           | p = 0.73 | p = 0.45 | p = 0.43 | p = 0.003 |          |
| **FIM scale**       |          |          |          |          |          |
| A continuous variable | 0.983 (0.971–0.996) | 0.984 (0.962–1.009) | 0.999 (0.974–1.025) | 0.999 (0.974–1.025) | 0.978 (0.963–0.994) |
| p = 0.010           | p = 0.07 | p = 0.90 | p = 0.90 | p = 0.004 |          |
| Full, 126           | 1        | 1        | 1        | 1        | 1        |
| <126                | 1.204 (0.790–1.838) | 0.710 (0.300–1.682) | 0.622 (0.177–2.186) | 0.651 (0.323–1.312) | 1.720 (1.062–2.785) |
| p = 0.39            | p = 0.44 | p = 0.46 | p = 0.23 | p = 0.027 |          |

(Continued)
| Covariate/parameter | OS | CNS-CE as first event | LMD recurrence | Neurologic death | Non-neurologic death |
|---------------------|----|----------------------|---------------|------------------|----------------------|
|                     | Crude HR (95% CI) | Crude HR (95% CI) | Crude HR (95% CI) | Crude HR (95% CI) | Crude HR (95% CI) |
|                     | p-value | p-value | p-value | p-value | p-value |
| Histological subtype of primary cancer | | | | | |
| Lung adenocarcinoma | 1 | 1 | 1 | 1 | 1 |
| Lung non-adenocarcinoma | 0.905 (0.443–1.848) | 0.734 (0.087–6.200) | 0 | 1.755 (0.483–6.374) | 1.086 (0.517–2.280) |
|                      | p = 0.78 | p = 0.78 | p < 0.0001 | p = 0.39 | p = 0.83 |
| Breast | 0.677 (0.363–1.262) | 1.880 (0.599–5.905) | 1.949 (0.359–10.583) | 4.445 (1.964–10.062) | 0.566 (0.286–1.119) |
|                      | p = 0.220 | p = 0.279 | p = 0.439 | p < 0.0001 | p = 0.102 |
| Others or unknown | 1.659 (0.966–2.850) | 3.608 (1.339–9.722) | 3.113 (0.781–12.406) | 3.653 (1.385–9.640) | 0.920 (0.443–1.913) |
|                      | p = 0.07 | p = 0.011 | p = 0.11 | p = 0.009 | p = 0.50 |
| Number of brain metastatic lesions at diagnosis | | | | | |
| Solitary | 1 | 1 | 1 | 1 | 1 |
| 2–3 metastatic foci | 1.165 (0.754–1.801) | 0.831 (0.338–2.042) | 0.420 (0.090–1.966) | 0.816 (0.388–1.717) | 1.178 (0.730–1.900) |
|                      | p = 0.49 | p = 0.69 | p = 0.27 | p = 0.59 | p = 0.50 |
| Extent of resection | | | | | |
| En-bloc gross total | 1 | 1 | 1 | 1 | 1 |
| Less than gross total | 1.221 (0.555–2.687) | 1.735 (0.547–5.503) | 0 | 1.506 (0.553–4.102) | 1.352 (0.496–3.886) |
|                      | p = 0.62 | p = 0.35 | p = 0.27 | p = 0.59 | p = 0.50 |
| The technique of SIB | | | | | |
| Not applied | 1 | 1 | 1 | 1 | 1 |
| Attempted | 1.154 (0.743–1.793) | 0.494 (0.191–1.273) | 0.549 (0.142–2.118) | 0.491 (0.219–1.098) | 1.256 (0.770–2.049) |
|                      | p = 0.52 | p = 0.14 | p = 0.38 | p = 0.08 | p = 0.36 |
| Status and control of extracranial disease | | | | | |
| Stable or controlled | 1 | 1 | 1 | 1 | 1 |
| Uncontrolled yet | 2.005 (1.180–3.406) | 0.359 (0.153–0.841) | 0.274 (0.080–0.931) | 0.340 (0.174–0.663) | 4.137 (1.937–8.836) |
|                      | p = 0.010 | p = 0.018 | p = 0.038 | p = 0.002 | p < 0.001 |
| RTOG RPA class | | | | | |
| Class I | 1 | 1 | 1 | 1 | 1 |
| Class II | 1.734 (0.992–3.031) | 0.362 (0.153–0.853) | 0.343 (0.089–1.192) | 0.344 (0.175–0.675) | 4.677 (1.942–11.262) |
|                      | p = 0.053 | p = 0.020 | p = 0.09 | p = 0.002 | p < 0.001 |

OS, overall survival; PCI, primary cranial irradiation; CNS-CE, central nervous system-composite endpoint; LMD, leptomeningeal disease; KPS, Karnofsky performance status; HS-WBRT, hippocampus-sparing whole-brain radiotherapy; ECOG, Eastern Cooperative Oncology Group; FIM, functional independence measure; SIB, simultaneous integrated boost; RTOG RPA, Radiation Therapy Oncology Group recursive partitioning analysis.

NA, Not Applicable.

Bold letters indicate statistically significant values (p < 0.05).
receiving upfront SRS/SRT tailored to the metastatic lesion(s) without immediate WBRT (16, 18). Interestingly, the only independent predictor for LMD recurrence was surgical resection per se after controlling for other confounders (18).

Similarly, we found that all events associated with LMD recurrence were present exclusively in the subcohort with resection cavities post-craniotomy, but not in the subcohort with intact BMs. Two rational explanations may account for such a drastic difference in the cumulative incidence of LMD recurrence between subcohorts. First, the consistent delivery of WBRT would naturally reduce the probability of leptomeningeal spreading, and this clinical benefit resulting from WBRT was documented in other studies (19, 20). Second, with intraoperative tumor spill during neurosurgical resection probably, the margins around the leptomeninges could adversely be the origins of CNS progression that cannot be eradicated completely by WBRT (21).

The majority of our results and discussion focused on oncological outcomes including CNS progression and cancer-related causes of death (non-neurologic, neurologic, respectively) based considerably on a competing-risks approach. It was acknowledged that neuro-oncological outcomes were indeed the main research aim addressed in the current manuscript. All of our patients received their course of whole-brain irradiation relying on the technique of hippocampus-sparing whole-brain radiotherapy which was designed and delivered in a standardized and consistent fashion, and we believe our study purpose and niche are innovative, which can easily be distinguished from past histological research. First, the so-called whole-brain irradiation used in most of the histological studies was traditional and conventional WBRT, which were basically bilateral opposed fields without utilizing the modern techniques of intensity-modulated radiotherapy or volume-modulated arc therapy. Second, the oncological outcomes addressed in the previous histological studies were mainly classical survival analyses such as Kaplan–Meier survival probability estimation and Cox proportional hazards regression model analyses. It was acknowledged that additional comprehensive analyses relying on a competing-risks approach were utilized in our study, attempting to explore and clarify the cancer-specific causes of death (neurologic or non-neurologic, mutually exclusive) and ultimately the more specific neuro-oncological endpoints including CNS progression measured as a composite endpoint (CNS-CE) and CNS progression manifesting as LMD recurrence.

The study had no stereotyped control group managed with conventional WBRT without the strategy of hippocampus sparing; however, we consider it unethical to conduct a prospective study with a control group allocated to conventional WBRT without hippocampus sparing. We consider that HS-WBRT indeed contributed to comparable neuro-oncological outcomes and superior neurocognitive outcomes. Moreover, two relevant randomized controlled trials (RCTs) integrated with a control arm of WBRT without hippocampal avoidance was reported in 2020 (22, 23). We also acknowledge that the confounding effect of molecular target therapy or immunotherapy was not included in our research protocol. Frankly speaking, this study was launched initially by neurosurgeons and conducted chiefly by radiation oncologists.
The majority of our enrolled patients harboring newly diagnosed brain oligometastases at enrollment had not received molecular target therapy since they had no idea about their cancer diagnosis while being brought to an emergency department due to their active neurological symptoms.

Further prospective research comparing treatment effectiveness between HS-WBRT and upfront SRS/SRT without immediate WBRT is warranted. For patients with brain oligometastases, some neurosurgeons/physicians prefer upfront SRS/SRT, deferring WBRT until intracranial failure. By contrast, HS-WBRT would provide patients harboring brain oligometastases better intracranial tumor control without compromising neuropsychological outcomes than would upfront SRS without immediate WBRT.

Moreover, in this era of targeted therapy or immunotherapy, choosing among anticancer agents has been increasingly tailored to the molecular characterization in each distinct cancer individually. Previously, the challenges of unsatisfactory control over brain metastases have been attributed to a lack of CNS penetration of anticancer medication. Promisingly, recent studies have supported the role of certain targeted therapies in managing cancer patients with CNS metastases/progression based on the histopathology of primary malignancies (24, 25).

In the future, it merits innovative research projects addressing and determining whether administration of HS-WBRT can be postponed until CNS progression has occurred or replaced by upfront SRS/SRT integrated into first-line systemic treatment with targeted therapy for managing brain oligometastases without leptomeningeal spreading.

CONCLUSIONS

HS-WBRT has achieved favorable oncological outcomes by restricting the dose irradiating the hippocampus during WBRT. Oncological outcomes including neurologic/non-neurologic death after the HS-WBRT differ greatly between patients with intact BMs and those with cavities post-craniotomy, indicating they are clinically distinct subgroups; patients with resection cavities had a significantly increased likelihood of CNS progression (local failure, distant brain recurrence, or LMD recurrence) which might be associated with neurologic death eventually.

DATA AVAILABILITY STATEMENT

The original contributions presented in this study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Chang Gung Medical Foundation Institutional Review Board, Taoyuan, Taiwan, and the IRB numbers are IRB 101-4151B and 103-1090C. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

S-YL, C-CC, and D-LT contributed to the study conception and design. S-YL, P-CP, C-LW, Y-MW, C-CL, C-HL, K-CW, and W-CC performed chart reviews for clinical data, follow-up, and data collection and maintained the clinical database. S-YL, C-CY, and D-LT did the data analyses, performed the statistical testing, and had access to the raw data. C-CY, C-CC, and K-CW provided the infrastructural support for this study. The manuscript was drafted by S-YL, edited by D-LT and C-CC, and submitted for comments to all contributing authors. All authors approved the final version of the manuscript.

FUNDING

This study was supported by research grants (CMRPG3J0101, CMRPG2G0473, CMRPG3J1012) from Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan, R.O.C.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.784635/full#supplementary-material

REFERENCES

1. Maclean J, Fersht N, Singhera M, Mulholland P, McKee O, Kitchen N, et al. Multi-Disciplinary Management for Patients With Oligometastases to the Brain: Results of a 5 Year Cohort Study. Radiat Oncol (2013) 8:156. doi: 10.1186/1748-717X-8-156

2. Network NCC.. Central Nervous System Cancers. (Version 1.2021) (2021). [cited June 4, 2021]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.

3. Scoville WB, Milner B. Loss of Recent Memory After Bilateral Hippocampal Lesions. J Neuropsychiatr Clin Neurosci (2000) 12(1):103–13. doi: 10.1176/jnp.12.1.103-a

4. Rola R, Raber J, Rizk A, Otsuka S, VandenBerg SR, Hohneke D, et al. Radiation-Induced Impairment of Hippocampal Neurogenesis Is Associated With Cognitive Deficits in Young Mice. Exp Neurol (2004) 188(2):316–30. doi: 10.1016/j.expneurol.2004.05.005

5. Lam LCW, Leung SF, Chan YL. Progress of Memory Function After Radiation Therapy in Patients With Nasopharyngeal Carcinoma. J Neuropsychiatr Clin Neurosci (2003) 15(1):90–7. doi: 10.1176/appi.neuropsych.15.1.90

6. Ali AN, Ogunleye T, Hardy CW, Shu HK, Curran WJ, Crocker IR. Improved Hippocampal Dose With Reduced Margin Radiotherapy for Glioblastoma Multiforme. Radiat Oncol (2014) 9:20. doi: 10.1186/1748-717x-9-20

7. Oskan F, Ganswindt U, Schwarz SB, Manapov F, Belka C, Niyazi M. Hippocampal Sparing in Whole-Brain Radiotherapy. Strahlenther Onkol (2014) 190(4):337–41. doi: 10.1007/s00066-013-0518-8

8. Tsai P-F, Yang C-C, Chuang C-C, Huang T-Y, Wu Y-M, Pai P-C, et al. Hippocampal Dosimetry Correlates With the Change in Neurocognitive Function After Hippocampal Sparing During Whole Brain Radiotherapy: A
Prospective Study. *Radiat Oncol* (2015) 10(1):1–15. doi: 10.1186/s13014-015-0562-x
9. Brown PD, Colmer HG, White L, Fitzgerald N, Isom S, Bourland JD, et al. Competing Risk Analysis of Neurologic Versus Nonneurologic Death in Patients Undergoing Radiosurgical Salvage After Whole-Brain Radiation Therapy Failure: Who Actually Dies of Their Brain Metastases? *Int J Radiat Oncol Biol Phys* (2015) 92(5):1008–15. doi: 10.1016/j.ijrobp.2015.04.032
10. McTyre ER, Johnson AG, Ruiz J, Isom S, Lucas JT, Hinson WH, et al. Predictors of Neurologic and Nonneurologic Death in Patients With Brain Metastasis Initially Treated With Upfront Stereotactic Radiosurgery Without Whole-Brain Radiation Therapy. *Neuro-Oncology* (2017) 19(4):558–66. doi: 10.1093/neuonc/nox184
11. McCrory E, Ayala-Peacock D, Contessa J, Corso C, Chiang V, Chung C, et al. Multi-Institutional Competing Risks Analysis of Distant Brain Failure and Salvage Patterns After Upfront Radiosurgery Without Whole-Brain Radiotherapy for Brain Metastasis. *Ann Oncol* (2018) 29(2):497–503. doi: 10.1093/annonc/mdy740
12. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *J Am Stat Assoc* (1999) 94(446):496–509. doi: 10.2307/2670170
13. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. *N Engl J Med* (2020) 383(21):2018–29. doi: 10.1056/NEJMoa2027187
14. Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao DX, Serizawa T, et al. Evaluation of First-Line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases The FIRE-SCLC Cohort Study. *JAMA Oncol* (2020) 6(7):1028–37. doi: 10.1001/jamaoncol.2020.1271
15. Nayar G, Ejikeme T, Chongthaidikiet P, Elsamadicy AA, Blackwell KL, Clarke JM, et al. Leptomeningeal Disease: Current Diagnostic and Therapeutic Strategies. *Oncotarget* (2017) 8(42):73312–28. doi: 10.18632/oncotarget.20272
16. Nguyen TK, Sahgal A, Detsky J, Atenafu EG, Myrehaug S, Tseng CL, et al. Predictors of Leptomeningeal Disease Following Hypofractionated Stereotactic Radiotherapy for Intact and Resected Brain Metastases. *Neuro-Oncology* (2020) 22(1):84–93. doi: 10.1093/neuonc/noz144
17. Wang N, Bertalan MS, Brastianos PK. Leptomeningeal Metastasis From Systemic Cancer: Review and Update on Management. *Cancer* (2018) 124 (1):21–35. doi: 10.1002/cncr.30911
18. Atalar B, Modlin LA, Choi CYH, Adler JR, Gibbs IC, Chang SD, et al. Risk of Leptomeningeal Disease in Patients Treated With Stereotactic Radiosurgery Targeting the Postoperative Resection Cavity for Brain Metastases. *Int J Radiat Oncol Biol Phys* (2013) 87(4):713–8. doi: 10.1016/j.ijrobp.2013.07.034
19. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AG, et al. Postoperative Stereotactic Radiosurgery Compared With Whole Brain Radiotherapy for Resected Metastatic Brain Disease (NCCTG N107C/CEC.3): A Multicentre, Randomised, Controlled, Phase 3 Trial. *Lancet Oncol* (2017) 18 (8):1049–60. doi: 10.1016/s1470-2045(17)30441-2
20. Prabhu RS, Turner BE, Asher AL, Marcom SR, Fivash JB, Foreman PM, et al. A Multi-Institutional Analysis of Presentation and Outcomes for Leptomeningeal Disease Recurrence After Surgical Resection and Radiosurgery for Brain Metastases. *Neuro-Oncology* (2019) 21(8):1049–59. doi: 10.1093/neuonc/noz049
21. Hsieh J, Elson P, Otvos B, Rose J, Loftus C, Rahmathulla G, et al. Tumor Progression in Patients Receiving Adjutant Whole-Brain Radiotherapy vs Localized Radiotherapy After Surgical Resection of Brain Metastases. *Neuro-Oncology* (2015) 17(4):411–20. doi: 10.1227/NEU.0000000000000626
22. Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology Cc001. *J Clin Oncol* (2020) 38(10):1019–25. doi: 10.1200/jco.19.02767
23. Yang WC, Chen YF, Yang CC, Wu PF, Chan HM, Chen JL, et al. Hippocampal Avoidance Whole-Brain Radiotherapy Without Memantine in Preserving Neurocognitive Function for Brain Metastases: A Phase II Blinded Randomized Trial. *Neuro Oncol* (2020) 23(3):478–86. doi: 10.1093/neuonc/noaa193
24. Yu X, Sheng J, Pan G, Fan Y. Real-World Utilization of EGFR TKIs and Prognostic Factors for Survival in EGFR-Mutated non-Small Cell Lung Cancer Patients With Brain Metastases. *Int J Cancer* (2021) 149(5):1211–8. doi: 10.1002/ijc.36731
25. Hendriks LEL, Boomsma G, Mourlantte J, Henon C, Mezquita L, Ferrara R, et al. Survival of Patients With non-Small Cell Lung Cancer Having Leptomeningeal Metastases Treated With Immune Checkpoint Inhibitors. *Eur J Cancer* (2019) 116:182–9. doi: 10.1016/j.ejca.2019.05.019

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed and endorsed by the publisher.

**Copyright © 2022 Lin, Tsan, Chuang, Yang, Pai, Wang, Wu, Lee, Lin, Wei and Chou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**